Enrolment begins into Phase III trial evaluating anti-coronavirus hyperimmune IVIG in adults hospitalised with COVID-19

The global placebo-controlled ITAC trial of the investigational IVIG, which is derived from the plasma of individuals who have recovered from COVID-19 and have developed neutralizing antibodies to SARS-CoV-2, will include remdesivir as standard of care.

Source:

Biospace Inc.